Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pharmacological blockade of the mineralocorticoid receptor (MR) ameliorates end-organ damage in chronic heart failure. However, the clinical use of available steroidal MR antagonists is restricted because of concomitant hyperkalemia especially in patients with diminished kidney function. We have recently identified a novel nonsteroidal MR antagonist, finerenone, which uniquely combines potency and selectivity toward MR. Here, we investigated the tissue distribution and chronic cardiorenal end-organ protection of finerenone in comparison to the steroidal MR antagonist, eplerenone, in 2 different preclinical rat disease models. Quantitative whole-body autoradiography revealed that [C]-labeled finerenone equally distributes into rat cardiac and renal tissues. Finerenone treatment prevented deoxycorticosterone acetate-/salt-challenged rats from functional as well as structural heart and kidney damage at dosages not reducing systemic blood pressure. Finerenone reduced cardiac hypertrophy, plasma prohormone of brain natriuretic peptide, and proteinuria more efficiently than eplerenone when comparing equinatriuretic doses. In rats that developed chronic heart failure after coronary artery ligation, finerenone (1 mg·kg·d), but not eplerenone (100 mg·kg·d) improved systolic and diastolic left ventricular function and reduced plasma prohormone of brain natriuretic peptide levels. We conclude that finerenone may offer end-organ protection with a reduced risk of electrolyte disturbances.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical data showed that the kidney and cardiovascular benefits of finerenone were associated with potent antiinflammatory and antifibrotic effects through inhibition of overactivation of the mineralocorticoid receptor.6,[10][11][12][13]23”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [11]
In the citing paper
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone has been shown to have potent anti-inflammatory and antifibrotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its benefits in renal outcome and HHF [67–70].”
In the citing paper
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone has been shown to have potent anti-inflammatory and antifibrotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its benefits in renal outcome and HHF [67–70].”
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · cited 1×
“The steroidal MRAs spironolactone and eplerenone have been proven to reduce mortality in patients with symptomatic heart failure.(5,6,15) However, the broad application of these drugs FIGURE 4.”
BackgroundPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Swedberg, K., Eneroth, P., Kjekshus, J., & Wilhelmsen, L. (1990) · Circulation · doi:10.1161/01.cir.82.5.1730 · Cited by 1,153
Arzneimittelforschung: Durch Innovationen zum Markterfolg
Sedlacek, H.-H. (2015) · De Gruyter eBooks · doi:10.1515/9783110403527 · Cited by 699
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S.-Y., & Zannad, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht187 · Cited by 591 · cited 1×
“In these patients, 5 and 10 mg/d of finerenone was at least as effective as spironolactone 25 or 50 mg/d in decreasing BNP, NT-pro-BNP, and urinary albumin, but it was associated with lower increases in serum potassium, lower incidences of hyperkalaemia, and worsening of renal function.(31)”
BackgroundSelf-citationThree new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
de Gasparo, M., Joss, U., Ramjoué, H. P., Whitebread, S. E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., & Schmidlin, J. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22580-0 · Cited by 343 · cited 1×
“A commonly used dose of eplerenone that protects from heart injury in rat MI or rat hypertension models is 100 mg$kg21$d21,(22) whereas eplerenone already affects renal electrolyte handling at doses as low as 3 mg/kg.(17,18,23) Eplerenone has been investigated in several preclinical rat models including the chronic MI…”
BackgroundBärfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa‐Pérez, S., Heckroth, H., Nitsche, A., Ergüden, J., Gielen‐Haertwig, H., Schlemmer, K., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200081 · Cited by 270 · cited 4×
“Finerenone was previously identified as a novel nonsteroidal, potent, and selective MRA.(11,12) We compared in this study the efficacy of different doses of finerenone in 2 preclinical chronic models of heart failure.”
BackgroundMethodResultSelf-citationMineralocorticoid Receptors: Distribution and Activation
Funder, J. W. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2344-2 · Cited by 229 · cited 2×
“Aldosterone acts through its specific nuclear hormone receptor, the mineralocorticoid receptor (MR), which is predominantly expressed in kidney, colon, vessels, and the heart.(4) MR contributes to volume, sodium, and potassium homeostasis through renal tubular epithelial cells located in the distal tubule and the coll…”
Backgroundvan den Meiracker, A. H., Baggen, R. G., Pauli, S., Lindemans, A., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 187
Research works printed but not linked: 3
- Delcayre, 1999, 43, 7
- Bauersachs, 2013, 34, 2426
- Platt, 1972, Arzneimittelforschung, 22, 1801
Cited by
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationFinerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407107 · Cited by 893
Self-citationBakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Self-citationSteroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
“Compared with eplerenone in models of cardiac fibrosis, finerenone also demonstrated qualitatively different effects on pro-fibrotic gene expression and measures of inflammation and fibrosis.(62,68) However, the benefits of MRAs on kidney and cardiac outcomes need to be balanced against the risk of hyperkalaemia.”
BackgroundInfluentialSelf-citationFilippatos, G., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw132 · Cited by 446
Self-citation
Metadata
- Authors
- Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S.
- Affiliations
- Bayer (Germany) (DE)
- Corresponding author
- Kolkhof, Peter
- Delbeck, Martina
- Eitner, Frank
- Albrecht-Küpper, Barbara
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2014-07
- Volume
- 64
- Issue
- 1
- Pages
- 69-78
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2079169053
- Cited by
- 430
- References
- 28
- Citations by year
- 2026: 59 · 2025: 52 · 2024: 45 · 2023: 50 · 2022: 60 · 2021: 37 · 2020: 21 · 2019: 26 · 2018: 12 · 2017: 21 · 2016: 19 · 2015: 24 · 2014: 4
- FWCI
- 18.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cardiovascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Society of Cardiology
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- finerenone, mineralocorticoid receptor antagonists, eplerenone, cardiorenal protection, chronic heart failure, cardiac hypertrophy, proteinuria, brain natriuretic peptide, left ventricular function, tissue distribution, hyperkalemia, coronary artery ligation, desoxycorticosterone acetate, salt loading, chronic kidney disease
- MeSH terms
- Eplerenone, Mineralocorticoid Receptor Antagonists, Animals, Autoradiography, Disease Models, Animal, Cardiomegaly, Heart Failure, Kidney Diseases, Male, Naphthyridines, Peptide Fragments, Spironolactone, Tissue Distribution, Rats, Sprague-Dawley, Rats, Wistar, Natriuretic Peptide, Brain, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury. https://app.cochat.ai/papers/10.1097/fjc.0000000000000091
- The paper
- Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014). Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0000000000000091
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.